Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+9.61%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$3.86B
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,919
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| 1 |
Kenvue
KVUE
|
$439M |
| 2 |
AT&T
T
|
$437M |
| 3 |
Cummins
CMI
|
$427M |
| 4 |
Bunge Global
BG
|
$340M |
| 5 |
DaVita
DVA
|
$232M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$453M |
| 2 |
AbbVie
ABBV
|
$447M |
| 3 |
Phillips 66
PSX
|
$441M |
| 4 |
D.R. Horton
DHI
|
$440M |
| 5 |
Booking.com
BKNG
|
$405M |
Sector Composition
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 11.92% |
| 4 | Technology | 11.17% |
| 5 | Healthcare | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Crinetics Pharmaceuticals
CRNX
$3.3B
| $47.3K | ﹤0.01% |
+1,011
| New | +$47.3K |
|
1252
Supernus Pharmaceuticals
SUPN
$2.58B
| $45.9K | ﹤0.01% |
1,346
+716
| +114% | +$24.4K |
|
1253
BridgeBio Pharma
BBIO
$10.3B
| $45.5K | ﹤0.01% |
+1,473
| New | +$45.5K |
|
1254
Dyne Therapeutics
DYN
$1.92B
| $45.4K | ﹤0.01% |
+1,600
| New | +$45.4K |
|
1255
Madrigal Pharmaceuticals
MDGL
$10B
| $45.4K | ﹤0.01% |
+170
| New | +$45.4K |
|
1256
Krystal Biotech
KRYS
$4.28B
| $44.8K | ﹤0.01% |
+252
| New | +$44.8K |
|
1257
Sarepta Therapeutics
SRPT
$1.89B
| $44.5K | ﹤0.01% |
+344
| New | +$44.5K |
|
1258
Badger Meter
BMI
$5.39B
| $44.5K | ﹤0.01% |
275
+58
| +27% | +$9.39K |
|
1259
Cars.com
CARS
$838M
| $44.2K | ﹤0.01% |
2,571
+919
| +56% | +$15.8K |
|
1260
Rhythm Pharmaceuticals
RYTM
$6.67B
| $44.1K | ﹤0.01% |
+1,018
| New | +$44.1K |
|
1261
BioMarin Pharmaceuticals
BMRN
$10.7B
| $43.9K | ﹤0.01% |
+503
| New | +$43.9K |
|
|
BPMC
1262
DELISTED
Blueprint Medicines
BPMC
| $43.9K | ﹤0.01% |
+463
| New | +$43.9K |
|
1263
Natera
NTRA
$22.9B
| $43.9K | ﹤0.01% |
+480
| New | +$43.9K |
|
|
CERE
1264
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $43.7K | ﹤0.01% |
+1,035
| New | +$43.7K |
|
1265
DoubleVerify
DV
$2.49B
| $43.7K | ﹤0.01% |
1,244
+560
| +82% | +$19.7K |
|
|
ALPN
1266
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $43.4K | ﹤0.01% |
+1,095
| New | +$43.4K |
|
1267
Immunovant
IMVT
$2.89B
| $43.4K | ﹤0.01% |
+1,343
| New | +$43.4K |
|
1268
Revolution Medicines
RVMD
$7.59B
| $42.7K | ﹤0.01% |
+1,326
| New | +$42.7K |
|
1269
Alnylam Pharmaceuticals
ALNY
$59.7B
| $42.6K | ﹤0.01% |
+285
| New | +$42.6K |
|
1270
Altimmune
ALT
$331M
| $42.3K | ﹤0.01% |
+4,159
| New | +$42.3K |
|
1271
Roivant Sciences
ROIV
$8.82B
| $42.1K | ﹤0.01% |
+3,999
| New | +$42.1K |
|
1272
Ionis Pharmaceuticals
IONS
$9.59B
| $42.1K | ﹤0.01% |
+971
| New | +$42.1K |
|
1273
Vericel Corp
VCEL
$1.69B
| $41.9K | ﹤0.01% |
+805
| New | +$41.9K |
|
1274
BlackLine
BL
$3.36B
| $41.7K | ﹤0.01% |
+646
| New | +$41.7K |
|
1275
Insmed
INSM
$30.8B
| $41.7K | ﹤0.01% |
+1,536
| New | +$41.7K |
|